{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:06:10Z","timestamp":1791237970916,"version":"4.1.0"},"reference-count":143,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019304","name":"Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019304","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019305","name":"Manipal Academy of Higher Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019305","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.ejphar.2022.175147","type":"journal-article","created":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T18:25:53Z","timestamp":1657391153000},"page":"175147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Treatments for psoriasis: A journey from classical to advanced therapies. How far have we reached?"],"prefix":"10.1016","volume":"929","author":[{"given":"Gangadhar","family":"Hari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoop","family":"Kishore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2017-9533","authenticated-orcid":false,"given":"Sreedhara Ranganath Pai","family":"Karkala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2022.175147_bib6","author":"AdisInsight"},{"key":"10.1016\/j.ejphar.2022.175147_bib7","author":"AdisInsight"},{"key":"10.1016\/j.ejphar.2022.175147_bib8","author":"AdisInsight"},{"key":"10.1016\/j.ejphar.2022.175147_bib9","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1074\/jbc.M207577200","article-title":"Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17","volume":"278","author":"Aggarwal","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2022.175147_bib10","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1358\/mf.2008.30.4.1185802","article-title":"Antipsoriatic microemulsion gel formulations for topical drug delivery of Babchi Oil (Psoralea corylifolia)","volume":"30","author":"Ali","year":"2008","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175147_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0163-7258(89)90071-5","article-title":"The pharmacology and pharmacokinetics of the retinoids","volume":"40","author":"Allen","year":"1989","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2022.175147_bib12","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s40257-018-0406-1","article-title":"Guselkumab: a review in moderate to severe plaque psoriasis","volume":"19","author":"Al-Salama","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.ejphar.2022.175147_bib13","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2021-eular.1002","article-title":"POS1042 efficacy and safety of Deucravacitinib, an oral, selective tyrosine kinase 2 (Tyk2) inhibitor, compared with placebo and Apremilast in moderate to severe plaque psoriasis: results from the phase 3 poetyk pso-1 study","volume":"80","author":"Armstrong","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejphar.2022.175147_bib14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s40257-018-0396-z","article-title":"Improvement in patient-reported outcomes (dermatology life quality index and the psoriasis symptoms and signs diary) with guselkumab in moderate-to-severe plaque psoriasis: results from the phase III VOYAGE 1 and VOYAGE 2 studies","volume":"20","author":"Armstrong","year":"2019","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.ejphar.2022.175147_bib15","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/0190-9622(91)70089-K","article-title":"Acitretin plus UVB therapy for psoriasis: comparisons with placebo plus UVB and acitretin alone","volume":"24","author":"Armstrong","year":"1991","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.ejphar.2022.175147_bib16","unstructured":"UR 101 - AdisInsight [WWW Document], n.d. URL https:\/\/adisinsight.springer.com\/drugs\/800052458 (accessed 12.15.21)."},{"key":"10.1016\/j.ejphar.2022.175147_bib17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1468-3083.1998.tb00948.x","article-title":"Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis","volume":"11","author":"Austad","year":"1998","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.ejphar.2022.175147_bib19","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0168-3659(00)00309-6","article-title":"Microemulsions for topical delivery of 8-methoxsalen","volume":"69","author":"Baroli","year":"2000","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejphar.2022.175147_bib20","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3390\/12030423","article-title":"Phenolic antioxidants identified by ESI-MS from yerba mat\u00e9 (Ilex paraguariensis) and green tea (Camelia sinensis) extracts","volume":"12","author":"Bastos","year":"2007","journal-title":"Molecules"},{"key":"10.1016\/j.ejphar.2022.175147_bib21","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3109\/14756366.2011.585986","article-title":"Comparative study of the effect of green and roasted water extracts of mate (Ilex paraguariensis) on glucosyltransferase activity of Streptococcus mutans","volume":"27","author":"Battagim","year":"2012","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejphar.2022.175147_bib22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.annder.2009.12.004","article-title":"La phototh\u00e9rapie UVB \u00e0 spectre \u00e9troit dans le psoriasis vulgaire : utilisation pratique et pr\u00e9conisations de la Soci\u00e9t\u00e9 Fran\u00e7aise de Photodermatologie","volume":"137","author":"Beani","year":"2010","journal-title":"Ann. Dermatol. Venereol."},{"key":"10.1016\/j.ejphar.2022.175147_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1556\/030.63.2016.1.1","article-title":"Il-12 family cytokines: general characteristics, pathogenic microorganisms, receptors, and signalling pathways","volume":"63","author":"Behzadi","year":"2016","journal-title":"Acta Microbiol. Immunol. Hung."},{"key":"10.1016\/j.ejphar.2022.175147_bib25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2147\/PTT.S294173","article-title":"Key signaling pathways in psoriasis: recent insights from antipsoriatic therapeutics","volume":"11","author":"Ben Abdallah","year":"2021","journal-title":"Psoriasis Targets Ther."},{"key":"10.1016\/j.ejphar.2022.175147_bib26","doi-asserted-by":"crossref","first-page":"5523","DOI":"10.1021\/jf2008343","article-title":"Chemical composition and antioxidant activity of yerba-mate (Ilex paraguariensis A.St.-Hil., Aquifoliaceae) extract as obtained by spray drying","volume":"59","author":"Bert\u00e9","year":"2011","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.ejphar.2022.175147_bib30","first-page":"1002","article-title":"Evaluation of risk of major adverse cardiovascular events with biologic therapy in patients with psoriasis","volume":"16","author":"Bissonnette","year":"2017","journal-title":"J. Drugs Dermatol. JDD"},{"key":"10.1016\/j.ejphar.2022.175147_bib31","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40265-018-0888-4","article-title":"Brodalumab: a review in moderate to severe plaque psoriasis","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2022.175147_bib32","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.ejphar.2022.175147_bib33","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/jamadermatol.2020.0723","article-title":"Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial","volume":"156","author":"Blauvelt","year":"2020","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.ejphar.2022.175147_bib34","first-page":"22","article-title":"Cyclosporine for plaque-type psoriasis","volume":"21","author":"Bogdonoff","year":"1991","journal-title":"Drug Ther."},{"key":"10.1016\/j.ejphar.2022.175147_bib35","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.ejphar.2022.175147_bib38","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1097\/CM9.0000000000001221","article-title":"A double-blind, randomized, placebo- and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis","volume":"133","author":"Cai","year":"2020","journal-title":"Chinese Med J"},{"key":"10.1016\/j.ejphar.2022.175147_bib39","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1055\/s-2003-45141","article-title":"Anti-inflammatory compounds of plant origin. Part I. Action on arachidonic acid pathway, nitric oxide and nuclear factor \u03ba B (NF-\u03baB)","volume":"69","author":"Calixto","year":"2003","journal-title":"Planta Med."},{"key":"10.1016\/j.ejphar.2022.175147_bib40","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s13555-018-0230-9","article-title":"Biosimilar drugs for psoriasis: principles, present, and near future","volume":"8","author":"Carrascosa","year":"2018","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.ejphar.2022.175147_bib42","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1365-2133.1996.tb01155.x","article-title":"8-MDP PWA for psoriasis: a comparison of a minimal phototoxic dose-based regimen with a skin-type approach","volume":"135","author":"Collins","year":"1996","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ejphar.2022.175147_bib44","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/0128071-200910010-00008","article-title":"Adalimumab: in plaque psoriasis","volume":"10","author":"Croom","year":"2009","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.ejphar.2022.175147_bib45","first-page":"116","article-title":"An Africa-wide overview of medicinal plant harvesting, conservation and health care","volume":"11","author":"Cunningham","year":"1998","journal-title":"Non Wood For. Prod."},{"key":"10.1016\/j.ejphar.2022.175147_bib46","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s40265-015-0439-1","article-title":"Apremilast: a review in psoriasis and psoriatic arthritis","volume":"75","author":"Deeks","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2022.175147_bib47","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cca.2012.05.007","article-title":"Serum interleukin-6 levels in response to methotrexate treatment in psoriatic patients","volume":"413","author":"Elango","year":"2012","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ejphar.2022.175147_bib48","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/j.1365-4632.2006.02911.x","article-title":"The treatment of psoriasis vulgaris: 1% topical methotrexate gel","volume":"45","author":"Eskicirak","year":"2006","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.ejphar.2022.175147_bib50","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1007\/s00403-001-0280-0","article-title":"Effect of vitamin D3 on the increased expression of bcl-xL in psoriasis","volume":"293","author":"Fukuya","year":"2002","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.ejphar.2022.175147_bib51","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1517\/17425255.4.3.305","article-title":"Etanercept: an overview of its role in the treatment of psoriasis","volume":"4","author":"Galindo","year":"2008","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.ejphar.2022.175147_bib52","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1007\/s00018-011-0757-8","article-title":"Cyclic AMP: a selective modulator of NF-\u03baB action","volume":"68","author":"Gerlo","year":"2011","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejphar.2022.175147_bib53","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0753-3322(02)00256-1","article-title":"Polyunsaturated fatty acids and inflammatory diseases","volume":"56","author":"Gil","year":"2002","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejphar.2022.175147_bib55","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.4049\/jimmunol.0803721","article-title":"IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells","volume":"183","author":"Goodman","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2022.175147_bib56","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2022.175147_bib57","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2022.175147_bib58","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40257-020-00512-4","article-title":"Malignancy rates in brodalumab clinical studies for psoriasis","volume":"21","author":"Gottlieb","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.ejphar.2022.175147_bib59","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/1523-1747.ep12499782","article-title":"Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation","volume":"98","author":"Gottlieb","year":"1992","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejphar.2022.175147_bib60","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jaad.2011.10.020","article-title":"The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study","volume":"67","author":"Gottlieb","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.ejphar.2022.175147_bib61","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2022.175147_bib62","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0190-9622(98)70322-6","article-title":"Kinetics of photosensitivity in bath-PUVA photochemotherapy","volume":"39","author":"Gruss","year":"1998","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.ejphar.2022.175147_bib63","doi-asserted-by":"crossref","first-page":"240","DOI":"10.2340\/0001555575240243","article-title":"The psoriasis life stress inventory: a preliminary index of psoriasis-related stress","volume":"75","author":"Gupta","year":"1995","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.ejphar.2022.175147_bib64","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.4049\/jimmunol.179.7.4313","article-title":"Cutting edge: an in vivo requirement for STAT3 signaling in T H 17 development and T H 17-dependent autoimmunity","volume":"179","author":"Harris","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2022.175147_bib65","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1365-2613.2009.00669.x","article-title":"Angiogenesis drives psoriasis pathogenesis","volume":"90","author":"Heidenreich","year":"2009","journal-title":"Int. J. Exp. Pathol."},{"key":"10.1016\/j.ejphar.2022.175147_bib67","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1056\/NEJMoa021359","article-title":"Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis","volume":"349","author":"Heydendael","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2022.175147_bib68","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","article-title":"Preventing and managing toxicities of high-dose methotrexate","volume":"21","author":"Howard","year":"2016","journal-title":"Oncol."},{"key":"10.1016\/j.ejphar.2022.175147_bib69","series-title":"Psoriasis Is a Serious Disease Deserving Global Attention","year":"2012"},{"key":"10.1016\/j.ejphar.2022.175147_bib71","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2174\/092986706776055698","article-title":"Cyclooxygenase inhibitory natural products: current status","volume":"13","author":"Jachak","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejphar.2022.175147_bib72","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.apsb.2019.11.006","article-title":"A novel S1P1 modulator IMMH002 ameliorates psoriasis in multiple animal models","volume":"10","author":"Jin","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejphar.2022.175147_bib73","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1365-2133.2008.08902.x","article-title":"Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin","volume":"160","author":"Johansen","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ejphar.2022.175147_bib75","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","article-title":"Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR)","volume":"151","author":"Kalb","year":"2015","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.ejphar.2022.175147_bib76","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/1346-8138.14096","article-title":"Safety of biologics in psoriasis","volume":"45","author":"Kamata","year":"2018","journal-title":"J. Dermatol. (Tokyo)"},{"key":"10.1016\/j.ejphar.2022.175147_bib77","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1046\/j.1365-2133.1998.02029.x","article-title":"Calcipotriene-induced improvement in psoriasis is associated with reduced interleukin-8 and increased interleukin-10 levels within lesions","volume":"138","author":"Kang","year":"1998","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ejphar.2022.175147_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000210836","article-title":"Dithranol: a review of the mechanism of action in the treatment of psoriasis vulgaris","volume":"3","author":"Kem\u00e9ny","year":"1990","journal-title":"Skin Pharmacol. Physiol."},{"key":"10.1016\/j.ejphar.2022.175147_bib79","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/archderm.1991.01680070072008","article-title":"Cyclosporine in psoriasis treatment: inhibition of keratinocyte cell-cycle progression in G1 independent of effects on transforming growth factor \u03b1\/epidermal growth factor receptor pathways","volume":"127","author":"Khandke","year":"1991","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.ejphar.2022.175147_bib80","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1038\/sj.onc.1208446","article-title":"[6]-Gingerol inhibits COX-2 expression by blocking the activation of p38 MAP kinase and NF-\u03baB in phorbol ester-stimulated mouse skin","volume":"24","author":"Kim","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.ejphar.2022.175147_bib81","article-title":"Roles of calcitonin gene-related peptide in the skin, and other physiological and pathophysiological functions","volume":"18","author":"Kim","year":"2021","journal-title":"Brain Behav. Immun. Health"},{"key":"10.1016\/j.ejphar.2022.175147_bib82","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.4049\/jimmunol.1102045","article-title":"Repression of cyclic adenosine monophosphate upregulation disarms and expands human regulatory T cells","volume":"188","author":"Klein","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2022.175147_bib83","first-page":"79","article-title":"A short summary of clinical types of psoriasis","volume":"3","author":"Koca","year":"2016","journal-title":"North. Clin. Istanbul."},{"key":"10.1016\/j.ejphar.2022.175147_bib84","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0190-9622(08)80228-9","article-title":"Fumaric acid therapy in psoriasis: results and side effects of 2 years of treatment","volume":"27","author":"Kolbach","year":"1992","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.ejphar.2022.175147_bib85","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1177\/1060028018809522","article-title":"Tildrakizumab: a review of phase II and III clinical trials","volume":"53","author":"Kolli","year":"2019","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejphar.2022.175147_bib86","series-title":"Cardiac Immunomodulation. The Heart in Rheumatic, Autoimmune and Inflammatory Diseases: Pathophysiology, Clinical Aspects and Therapeutic Approaches 681\u2013714","author":"K\u00f6nemann","year":"2017"},{"key":"10.1016\/j.ejphar.2022.175147_bib87","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1001\/archderm.134.11.1388","article-title":"Traditional Chinese medicine for the treatment of dermatologic disorders","volume":"134","author":"Koo","year":"1998","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.ejphar.2022.175147_bib88","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1046\/j.1529-8019.2003.01617.x","article-title":"Traditional Chinese medicine in dermatology","volume":"16","author":"Koo","year":"2003","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.ejphar.2022.175147_bib89","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/3908061","article-title":"The role of IL-17 and related cytokines in inflammatory autoimmune diseases","author":"Kuwabara","year":"2017","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.ejphar.2022.175147_bib90","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis \u2014 results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2022.175147_bib91","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1067\/mjd.2001.117046","article-title":"Treatment of psoriasis. Part 1. Topical therapy and phototherapy","volume":"45","author":"Lebwohl","year":"2001","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.ejphar.2022.175147_bib92","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2000073","article-title":"Trial of Roflumilast cream for chronic plaque psoriasis","volume":"383","author":"Lebwohl","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2022.175147_bib93","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1517\/14740330903393732","article-title":"A review of acitretin for the treatment of psoriasis","volume":"8","author":"Lee","year":"2009","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.ejphar.2022.175147_bib94","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1084\/jem.20030451","article-title":"Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris","volume":"199","author":"Lee","year":"2004","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejphar.2022.175147_bib95","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1016\/j.bmcl.2005.05.105","article-title":"Induction of apoptosis by a novel indirubin-5-nitro-3\u2032-monoxime, a CDK inhibitor, in human lung cancer cells","volume":"15","author":"Lee","year":"2005","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejphar.2022.175147_bib96","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jpba.2006.06.029","article-title":"LC-APCI-MS method for detection and analysis of tryptanthrin, indigo, and indirubin in Daqingye and Banlangen","volume":"43","author":"Liau","year":"2007","journal-title":"J. Pharmaceut. Biomed. Anal."},{"key":"10.1016\/j.ejphar.2022.175147_bib97","first-page":"1","article-title":"Adverse reactions to biologics in psoriasis","volume":"53","author":"Lockwood","year":"2017","journal-title":"Curr. Probl. Dermatol."},{"key":"10.1016\/j.ejphar.2022.175147_bib98","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.it.2012.11.005","article-title":"The IL-23\/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses","volume":"34","author":"Lowes","year":"2013","journal-title":"Trends Immunol."},{"key":"10.1016\/j.ejphar.2022.175147_bib99","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1146\/annurev.med.080708.082655","article-title":"Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies","volume":"61","author":"Major","year":"2010","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ejphar.2022.175147_bib100","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2147\/PTT.S101233","article-title":"Tacrolimus for the management of psoriasis: clinical utility and place in therapy","volume":"6","author":"Malecic","year":"2016","journal-title":"Psoriasis Targets Ther."},{"key":"10.1016\/j.ejphar.2022.175147_bib101","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1600-0625.2007.00690.x","article-title":"Chinese herbal medicine (Tuhuai extract) exhibits topical anti-proliferative and anti-inflammatory activity in murine disease models","volume":"17","author":"Man","year":"2008","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.ejphar.2022.175147_bib102","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.1016\/j.bmc.2004.08.027","article-title":"Anti-allergic principles from Thai zedoary: structural requirements of curcuminoids for inhibition of degranulation and effect on the release of TNF-\u03b1 and IL-4 in RBL-2H3 cells","volume":"12","author":"Matsuda","year":"2004","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejphar.2022.175147_bib103","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/eji.201242654","article-title":"E-cadherin interactions are required for Langerhans cell differentiation","volume":"43","author":"Mayumi","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ejphar.2022.175147_bib104","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s40257-018-0408-z","article-title":"Efficacy and safety of brodalumab in patients with moderate-to-severe plaque psoriasis and skin of color: results from the pooled AMAGINE-2\/-3 randomized trials","volume":"20","author":"McMichael","year":"2019","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.ejphar.2022.175147_bib106","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1684\/ejd.2011.1335","article-title":"Effect of methotrexate on serum levels of IL-22 in patients with psoriasis","volume":"21","author":"Meephansan","year":"2011","journal-title":"Eur. J. Dermatol."},{"key":"10.1016\/j.ejphar.2022.175147_bib107","first-page":"568","article-title":"Efficacy of tofacitinib for the treatment of moderate-to-severe chronic plaque psoriasis in patient subgroups from two randomised phase 3 trials","volume":"15","author":"Menter","year":"2016","journal-title":"J. Drugs Dermatol. JDD"},{"key":"10.1016\/j.ejphar.2022.175147_bib109","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1055\/s-2006-958107","article-title":"Lipoxygenase inhibition and antioxidant properties of protoberberine and aporphine alkaloids isolated from Mahonia aquifolium","volume":"61","author":"Misik","year":"1995","journal-title":"Planta Med."},{"key":"10.1016\/j.ejphar.2022.175147_bib110","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1365-2133.1997.tb08752.x","article-title":"Comparative efficacy of calcipotriol (MC903) cream and betamethasone 17-valerate cream in the treatment of chronic plaque psoriasis. A randomized, double-blind, parallel group multicentre study","volume":"136","author":"Molin","year":"1997","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ejphar.2022.175147_bib111","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/bjd.14947","article-title":"Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm\u00ae- and placebo-controlled trial (BRIDGE)","volume":"176","author":"Mrowietz","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ejphar.2022.175147_bib112","series-title":"A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 in Subjects with Moderate to Severe Psoriasis","author":"NCT03384745","year":"2017"},{"key":"10.1016\/j.ejphar.2022.175147_bib113","series-title":"A Study to Evaluate ABY-035 in Subjects with Moderate-To-Severe Plaque Psoriasis","author":"NCT03591887","year":"2018"},{"key":"10.1016\/j.ejphar.2022.175147_bib114","series-title":"Efficacy \u3001Safety and PK of SHR-1314 in Patients with Moderate-To-Severe Plaque Psoriasis","author":"NCT04839016","year":"2021"},{"key":"10.1016\/j.ejphar.2022.175147_bib116","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nri2622","article-title":"Skin immune sentinels in health and disease","volume":"9","author":"Nestle","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejphar.2022.175147_bib118","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/039463200601900204","article-title":"Leukocyte infiltration and mRNA expression of IL-20, IL-8 and TNF-R p60 in psoriatic skin is driven by TNF-\u03b1","volume":"19","author":"Ogilvie","year":"2006","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175147_bib119","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000250880","article-title":"Tissue changes in psoriatic plaques after oral administration of retinoid","volume":"157","author":"Orfanos","year":"1978","journal-title":"Dermatology"},{"key":"10.1016\/j.ejphar.2022.175147_bib121","doi-asserted-by":"crossref","DOI":"10.2310\/7750.2009.00022","article-title":"Adalimumab in the treatment of psoriasis: pooled efficacy and safety results from three pivotal studies","volume":"13","author":"Papp","year":"2009","journal-title":"J. Cutan. Med. Surg."},{"key":"10.1016\/j.ejphar.2022.175147_bib122","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1185\/03007990802215315","article-title":"Analytical approaches to reporting long-term clinical trial data","volume":"24","author":"Papp","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.ejphar.2022.175147_bib123","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jaad.2016.01.013","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study","volume":"74","author":"Papp","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.ejphar.2022.175147_bib124","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1365-2133.2012.11168.x","article-title":"Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study","volume":"167","author":"Papp","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ejphar.2022.175147_bib125","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/S0140-6736(21)00440-2","article-title":"IL17A\/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study","volume":"397","author":"Papp","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2022.175147_bib127","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjd.12266","article-title":"A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis","volume":"169","author":"Ports","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ejphar.2022.175147_bib128","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s13555-021-00554-4","article-title":"Efficacy and safety of netakimab, A novel anti-IL-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. Results of A 54-Week randomized double-blind placebo-controlled PLANETA clinical trial","volume":"11","author":"Puig","year":"2021","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.ejphar.2022.175147_bib129","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2174\/187153012802002901","article-title":"Classical to current approach for treatment of psoriasis: a review","volume":"12","author":"Rahman","year":"2012","journal-title":"Endocr. Metab. Immune Disord. - Drug Targets"},{"key":"10.1016\/j.ejphar.2022.175147_bib130","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2133.2012.10941.x","article-title":"Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension","volume":"167","author":"Reich","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ejphar.2022.175147_bib131","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus Secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2022.175147_bib132","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.yadr.2008.09.006","article-title":"Update on the natural history and systemic treatment of psoriasis","volume":"24","author":"Richardson","year":"2008","journal-title":"Adv. Dermatol."},{"key":"10.1016\/j.ejphar.2022.175147_bib133","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1172\/JCI111557","article-title":"Inhibition of T lymphocyte mitogenesis by 1,25-dihydroxyvitamin D3 (calcitriol)","volume":"74","author":"Rigby","year":"1984","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2022.175147_bib134","doi-asserted-by":"crossref","DOI":"10.1186\/s41927-019-0094-3","article-title":"Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics","volume":"3","author":"Ritchlin","year":"2019","journal-title":"BMC Rheumatol."},{"key":"10.1016\/j.ejphar.2022.175147_bib135","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.0022-202X.2005.23754.x","article-title":"Pharmacokinetics of 0.1% tacrolimus ointment after first and repeated application to adults with moderate to severe atopic dermatitis","volume":"125","author":"Rubins","year":"2005","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejphar.2022.175147_bib136","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1078\/0944-7113-00032","article-title":"In vitro keratinocyte antiproliferant effect of Centella asiatica extract and triterpenoid saponins","volume":"8","author":"Sampson","year":"2001","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ejphar.2022.175147_bib137","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1345\/aph.1M151","article-title":"Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis","volume":"43","author":"Scanlon","year":"2009","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejphar.2022.175147_bib138","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/ptr.1604","article-title":"Lipoxygenase inhibitors from natural plant sources. Part 2: medicinal plants with inhibitory activity on arachidonate 12-lipoxygenase, 15-lipoxygenase and leukotriene receptor antagonists","volume":"19","author":"Schneider","year":"2005","journal-title":"Phytother Res."},{"key":"10.1016\/j.ejphar.2022.175147_bib139","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.0906-6705.2004.00205.x","article-title":"Biology of tumor necrosis factor-\u03b1 - implications for psoriaris","volume":"13","author":"Schottelius","year":"2004","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.ejphar.2022.175147_bib140","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1016\/j.jid.2016.06.009","article-title":"Keratinocyte-derived IL-17e contributes to inflammation in psoriasis","volume":"136","author":"Senra","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejphar.2022.175147_bib141","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/1744666X.2019.1544493","article-title":"Tildrakizumab for the treatment of psoriasis","volume":"15","author":"Sinclair","year":"2019","journal-title":"Expet Rev. Clin. Immunol."},{"key":"10.1016\/j.ejphar.2022.175147_bib142","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1016\/j.jid.2017.05.004","article-title":"Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans","volume":"137","author":"Smith","year":"2017","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejphar.2022.175147_bib143","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1172\/JCI27179","article-title":"Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation","volume":"116","author":"Stratis","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2022.175147_bib144","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jaad.2019.08.026","article-title":"Recategorization of psoriasis severity: delphi consensus from the international psoriasis Council","volume":"82","author":"Strober","year":"2020","journal-title":"J. Am Dermatol."},{"key":"10.1016\/j.ejphar.2022.175147_bib145","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1365-2141.2005.05655.x","article-title":"Indirubin, a Chinese anti-leukaemia drug, promotes neutrophilic differentiation of human myelocytic leukaemia HL-60 cells","volume":"130","author":"Suzuki","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejphar.2022.175147_bib146","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1046\/j.1365-3156.1996.d01-91.x","article-title":"Management of psoriasis with Aloe vera extract in a hydrophilic cream: a placebo-controlled, double-blind study","volume":"1","author":"Syed","year":"1996","journal-title":"Trop. Med. Int. Health"},{"key":"10.1016\/j.ejphar.2022.175147_bib147","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0006-291X(80)80225-7","article-title":"Partial purification and characterization of a guanylate cyclase inhibitor with cytotoxic properties from the bitter melon (Momordica charantia)","volume":"94","author":"Takemoto","year":"1980","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2022.175147_bib148","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: Epidemiology","volume":"76","author":"Takeshita","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.ejphar.2022.175147_bib149","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01210","article-title":"Transcription factor retinoid-related orphan receptor \u03b3t: a promising target for the treatment of psoriasis","volume":"9","author":"Tang","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2022.175147_bib151","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jep.2008.01.036","article-title":"Toxicity studies on dermal application of plant extract of Plumbago zeylanica used in Ethiopian traditional medicine","volume":"117","author":"Teshome","year":"2008","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.ejphar.2022.175147_bib152","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044274","article-title":"Meta-analysis derived (MAD) transcriptome of psoriasis defines the \u201ccore\u201d pathogenesis of disease","volume":"7","author":"Tian","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2022.175147_bib153","unstructured":"Tofacitinib - pfizer - AdisInsight [WWW Document], n.d. URL https:\/\/adisinsight.springer.com\/drugs\/800019029 (accessed 12.19.21)."},{"key":"10.1016\/j.ejphar.2022.175147_bib154","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1016\/j.bbamcr.2014.05.014","article-title":"Cytokines and chemokines: at the crossroads of cell signalling and inflammatory disease","volume":"1843","author":"Turner","year":"2014","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"10.1016\/j.ejphar.2022.175147_bib155","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1097\/00007611-197607000-00017","article-title":"Betamethasone dipropionate ointment in the treatment of psoriasis and atopic dermatitis: a double-blind study","volume":"69","author":"Vanderploeg","year":"1976","journal-title":"South. Med. J."},{"key":"10.1016\/j.ejphar.2022.175147_bib156","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.clindermatol.2003.08.015","article-title":"Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-\u03b1) blockade in psoriasis and psoriatic arthritis","volume":"21","author":"Victor","year":"2003","journal-title":"Clin. Dermatol."},{"key":"10.1016\/j.ejphar.2022.175147_bib158","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1172\/JCI27180","article-title":"Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation","volume":"116","author":"Wang","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2022.175147_bib159","series-title":"Global Report on. Global Report on Psoriasis","author":"WHO","year":"2016"},{"key":"10.1016\/j.ejphar.2022.175147_bib160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13555-013-0023-0","article-title":"Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases","volume":"3","author":"Wittmann","year":"2013","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.ejphar.2022.175147_bib161","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.immuni.2007.11.016","article-title":"T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR\u03b1 and ROR\u03b3","volume":"28","author":"Yang","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.ejphar.2022.175147_bib162","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/S0140-6736(69)92297-1","article-title":"Hydroxyurea in the treatment of refractory psoriasis","volume":"294","author":"Yarbro","year":"1969","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2022.175147_bib163","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/13543784.2017.1274734","article-title":"The potential utility of tildrakizumab: an interleukin-23 inhibitor for the treatment of psoriasis","volume":"26","author":"Yiu","year":"2017","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejphar.2022.175147_bib164","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1084\/jem.20071094071408c","article-title":"Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses (Journal of Experimental Medicine","volume":"205","author":"Zaba","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejphar.2022.175147_bib165","article-title":"Zingiber zerumbet (L.) Smith: a review of its ethnomedicinal, chemical, and pharmacological uses","volume":"1\u201312","author":"Zakaria","year":"2011","journal-title":"Evid. base Compl. Alternative Med."},{"key":"10.1016\/j.ejphar.2022.175147_bib166","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41591-018-0003-0","article-title":"Differential glucose requirement in skin homeostasis and injury identifies a therapeutic target for psoriasis article","volume":"24","author":"Zhang","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2022.175147_bib167","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/0091270009343695","article-title":"Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis","volume":"50","author":"Zhou","year":"2010","journal-title":"J. Clin. Pharmacol."},{"issue":"1 13","key":"10.1016\/j.ejphar.2022.175147_bib168","first-page":"1","article-title":"Advances in the pathogenesis of psoriasis: from keratinocyte perspective","volume":"13","author":"Zhou","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejphar.2022.175147_bib169","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1152\/physiolgenomics.00157.2002","article-title":"Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array","volume":"13","author":"Zhou","year":"2003","journal-title":"Physiol. Genom."},{"key":"10.1016\/j.ejphar.2022.175147_bib170","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0006-291X(02)02357-4","article-title":"Vitamin D3 and analogues modulate the expression of CSF-1 and its receptor in human dendritic cells","volume":"297","author":"Zhu","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299922004083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299922004083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T23:06:20Z","timestamp":1757977580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299922004083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":143,"alternative-id":["S0014299922004083"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.175147","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatments for psoriasis: A journey from classical to advanced therapies. How far have we reached?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.175147","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"175147"}}